EverSource Wealth Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

EverSource Wealth Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$959	Sell	32 -409	-93%	-$11.6K	﹤0.01%	3977
2026 Q1	$13.2K	Buy	441 +409	+1,278%	+$13.5K	﹤0.01%	2765
2025 Q4	$1.05K	Sell	32 -277	-90%	-$8.94K	﹤0.01%	3697
2025 Q3	$10.7K	Sell	309 -99	-24%	-$3.17K	﹤0.01%	2791
2025 Q2	$11.4K	Buy	+408	New	+$10.9K	﹤0.01%	2724
2024 Q4	–	Sell	-32	Closed	-$921	–	3776
2024 Q3	$921	Hold	32	–	–	﹤0.01%	2746
2024 Q2	$853	Sell	32 -98	-75%	-$2.78K	﹤0.01%	2769
2024 Q1	$3.7K	Buy	+130	New	+$4.83K	﹤0.01%	2181

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EverSource Wealth Advisors's LKFT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 93% in Q2 2026, selling an estimated $11.6K and leaving 32 shares worth $959. The position accounts for ﹤0.01% of the portfolio, ranked #3977.

EverSource Wealth Advisors first reported a position in LKFT in Q1 2024 and has held it in 8 quarters since. The position peaked at $13.2K in Q1 2026. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

EverSource Wealth Advisors held 32 shares of Lakefront Biotherapeutics American Depositary Shares worth $959 as of Q2 2026.
EverSource Wealth Advisors sold 409 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $11.6K.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3977 holding.
EverSource Wealth Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2024 and has held it in 8 quarters since.
EverSource Wealth Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $13.2K in Q1 2026.
76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.